CORRESP Filing
Phio Pharmaceuticals Corp.
Date: Aug. 21, 2025 · CIK: 0001533040 · Accession: 0001683168-25-006371
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289621
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Registration Statement on Form S-3 Filed August 15, 2025 File No. 333-289621 Request for Acceleration of Effective Date
Dear Ms. Dickerson:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on August 22, 2025, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Amanda Brown of Hogan Lovells US LLP at (267) 675-4683. Also, please notify Ms. Brown when this request for acceleration has been granted.
Very truly yours,
PHIO PHARMACEUTICALS CORP.
Show Raw Text
CORRESP 1 filename1.htm PHIO PHARMACEUTICALS CORP. 411 Swedeland Road, Suite 23-1080 King of Prussia, PA 19406 August 21, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-3 Filed August 15, 2025 File No. 333-289621 Request for Acceleration of Effective Date Dear Ms. Dickerson: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on August 22, 2025, or as soon thereafter as possible. Please direct any questions or comments concerning this request to Amanda Brown of Hogan Lovells US LLP at (267) 675-4683. Also, please notify Ms. Brown when this request for acceleration has been granted. Very truly yours, PHIO PHARMACEUTICALS CORP. By: /s/ Robert J. Bitterman Name: Robert J. Bitterman Title: President and Chief Executive Officer cc: Amanda Brown, Hogan Lovells US LLP